image
Technology - Software - Application - NYSE - US
$ 10.6
0.0944 %
$ 1 B
Market Cap
353.33
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one ENFN stock under the worst case scenario is HIDDEN Compared to the current market price of 10.6 USD, Enfusion, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one ENFN stock under the base case scenario is HIDDEN Compared to the current market price of 10.6 USD, Enfusion, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one ENFN stock under the best case scenario is HIDDEN Compared to the current market price of 10.6 USD, Enfusion, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart ENFN

image
$11.5$11.5$11.0$11.0$10.5$10.5$10.0$10.0$9.5$9.5$9.0$9.0$8.5$8.515 Oct15 OctNov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '25
FINANCIALS
202 M REVENUE
15.51%
6.16 M OPERATING INCOME
-48.49%
3.92 M NET INCOME
-57.69%
34.7 M OPERATING CASH FLOW
35.30%
-13.9 M INVESTING CASH FLOW
-43.65%
-1.4 M FINANCING CASH FLOW
96.74%
52.9 M REVENUE
3.46%
1.58 M OPERATING INCOME
-46.86%
172 K NET INCOME
-93.00%
9.67 M OPERATING CASH FLOW
-40.15%
-2.66 M INVESTING CASH FLOW
4.04%
0 FINANCING CASH FLOW
100.00%
Balance Sheet Enfusion, Inc.
image
Current Assets 93.5 M
Cash & Short-Term Investments 54.5 M
Receivables 32 M
Other Current Assets 7.05 M
Non-Current Assets 49.7 M
Long-Term Investments 0
PP&E 39 M
Other Non-Current Assets 10.7 M
38.03 %22.33 %4.92 %27.24 %7.48 %Total Assets$143.3m
Current Liabilities 27.3 M
Accounts Payable 867 K
Short-Term Debt 6.08 M
Other Current Liabilities 20.4 M
Non-Current Liabilities 16.4 M
Long-Term Debt 14.2 M
Other Non-Current Liabilities 2.15 M
13.90 %46.64 %32.56 %4.92 %Total Liabilities$43.7m
EFFICIENCY
Earnings Waterfall Enfusion, Inc.
image
Revenue 202 M
Cost Of Revenue 64.9 M
Gross Profit 137 M
Operating Expenses 131 M
Operating Income 6.16 M
Other Expenses 2.24 M
Net Income 3.92 M
250m250m200m200m150m150m100m100m50m50m00202m(65m)137m(131m)6m(2m)4mRevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
67.82% GROSS MARGIN
67.82%
3.05% OPERATING MARGIN
3.05%
1.40% NET MARGIN
1.40%
3.86% ROE
3.86%
1.97% ROA
1.97%
1.93% ROIC
1.93%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Enfusion, Inc.
image
35m35m30m30m25m25m20m20m15m15m10m10m5m5m00(5m)(5m)(10m)(10m)202020202021202120222022202320232024202420252025
Net Income 3.92 M
Depreciation & Amortization 11.8 M
Capital Expenditures -3.64 M
Stock-Based Compensation 19 M
Change in Working Capital 0
Others -20 K
Free Cash Flow 31 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Enfusion, Inc.
image
ENFN has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 10
6. Ownership
Insider Ownership Enfusion, Inc.
image
Sold
0-3 MONTHS
550 K USD 6
3-6 MONTHS
1.05 M USD 7
6-9 MONTHS
26.1 K USD 1
9-12 MONTHS
622 K USD 4
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Clearwater Analytics and Enfusion Announce Election Deadline for Enfusion Shareholders to Elect Form of Merger Consideration BOISE, Idaho & CHICAGO--(BUSINESS WIRE)--Clearwater Analytics (NYSE: CWAN) (“Clearwater”) and Enfusion, Inc. (NYSE: ENFN) (“Enfusion”) today announced that the deadline for Enfusion shareholders of record to elect the form of merger consideration (the “Merger Consideration”) they wish to receive in connection with Clearwater's acquisition of Enfusion (the "Transaction") is 5:00 p.m. Eastern Time on April 16, 2025 (such deadline, as it may be extended, the "Election Deadline"). Enfusion sharehol. businesswire.com - 2 weeks ago
ENFUSION INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Enfusion, Inc. - ENFN NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Enfusion, Inc. (NYSE: ENFN) to Clearwater Analytics Holdings, Inc. (NYSE: CWAN). Under the terms of the proposed transaction, shareholders of Enfusion will receive $5.85 in cash and $5.40 in Clearwater Class A Common Stock for each share of Enfusion that they own. KSF is seeking to determine whether this consi. businesswire.com - 2 weeks ago
Enfusion, Inc. (ENFN) Lags Q4 Earnings and Revenue Estimates Enfusion, Inc. (ENFN) came out with quarterly earnings of $0.03 per share, missing the Zacks Consensus Estimate of $0.07 per share. This compares to earnings of $0.04 per share a year ago. zacks.com - 1 month ago
Enfusion Announces Fourth Quarter and Full Year 2024 Results NEW YORK & LONDON & HONG KONG--(BUSINESS WIRE)--Enfusion, Inc. ("Enfusion") (NYSE: ENFN), a leading provider of software-as-a-service (SaaS) solutions for investment managers, today announced financial results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter 2024 Financial Highlights: Total revenue was $52.9 million, up 13.9% compared to the same period in the prior year. Gross Profit was $36.5 million with a Gross Profit Margin of 69.0%. Adjusted Gross Profit was $3. businesswire.com - 1 month ago
Clearwater Analytics and Enfusion Announce Expiration of Hart-Scott-Rodino Act Waiting Period For Proposed Acquisition of Enfusion BOISE, Idaho--(BUSINESS WIRE)--Clearwater Analytics Holdings, Inc. (NYSE: CWAN) (“Clearwater” or the “Company”), a leading worldwide provider of SaaS-based investment management, accounting, reporting, and analytics solutions, and Enfusion, Inc. (NYSE: ENFN) (“Enfusion”), a leader in software-as-a-service solutions for the investment management and hedge fund industry, today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the “HSR A. businesswire.com - 1 month ago
ENFN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Enfusion, Inc. Is Fair to Shareholders NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Enfusion, Inc. (NYSE: ENFN) to Clearwater Analytics for $5.85 per share in cash and $5.40 per share in Clearwater Class A Common Stock is fair to Enfusion shareholders. Halper Sadeh encourages Enfusion shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh. businesswire.com - 1 month ago
Clearwater Analytics' Enfusion Infusion Offers Compelling Value Proposition, Analyst Upgrades Stock Piper Sandler analyst Arvind Ramnani upgraded the shares of Clearwater Analytics Holdings Inc CWAN from Neutral to Overweight and raised the price forecast from $28.00 to $36.00. benzinga.com - 1 month ago
Enfusion, Inc. (ENFN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation NEW YORK CITY, NY / ACCESS Newswire / February 19, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Enfusion, Inc. ("Enfusion") (NYSE:ENFN) and Clearwater Analytics. Investors who purchased Enfusion and continue to hold to the present are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ENFN. accessnewswire.com - 1 month ago
Bronstein, Gewirtz & Grossman, LLC Encourages Enfusion, Inc. (ENFN) Shareholders to Inquire about Securities Investigation NEW YORK CITY, NY / ACCESS Newswire / February 16, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Enfusion, Inc. ("Enfusion") (NYSE:ENFN) and Clearwater Analytics. Investors who purchased Enfusion and continue to hold to the present are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ENFN. accessnewswire.com - 2 months ago
Bronstein, Gewirtz & Grossman, LLC Is Investigating Enfusion, Inc. (ENFN) And Encourages Investors to Connect NEW YORK CITY, NY / ACCESS Newswire / February 12, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Enfusion, Inc. ("Enfusion") (NYSE:ENFN) and Clearwater Analytics. Investors who purchased Enfusion and continue to hold to the present are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ENFN. accessnewswire.com - 2 months ago
Bronstein, Gewirtz & Grossman, LLC Encourages Enfusion, Inc. (ENFN) Stockholders to Inquire about Securities Investigation NEW YORK CITY, NY / ACCESS Newswire / February 9, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Enfusion, Inc. ("Enfusion") (NYSE:ENFN) and Clearwater Analytics. Investors who purchased Enfusion and continue to hold to the present are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ENFN. accessnewswire.com - 2 months ago
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Enfusion, Inc. (ENFN) and Encourages Investors to Learn More About the Investigation NEW YORK CITY, NY / ACCESS Newswire / February 5, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Enfusion, Inc. ("Enfusion") (NYSE:ENFN) and Clearwater Analytics. Investors who purchased Enfusion and continue to hold to the present are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ENFN. accessnewswire.com - 2 months ago
8. Profile Summary

Enfusion, Inc. ENFN

image
COUNTRY US
INDUSTRY Software - Application
MARKET CAP $ 1 B
Dividend Yield 0.00%
Description Enfusion, Inc. provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. It provides portfolio management system, which generates a real-time investment book of record that consists of valuation and risk tools that allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and order and execution management system that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines. The company also offers accounting/general ledger system, a real-time accounting book of record for chief financial officers, chief operating officers, accountants, and operations teams; Enfusion analytics system, which enables CIOs, portfolio managers, traders, and analysts to analyze portfolios through time horizons and automate customized visualized reports for internal and external stakeholders; and technology-powered and managed services. Enfusion Inc. was incorporated in 2021 and is headquartered in Chicago, Illinois.
Contact 125 South Clark Street, Chicago, IL, 60603 https://www.enfusion.com
IPO Date Oct. 21, 2021
Employees 1143
Officers Ms. Valeria Gutowski Chief Accounting Officer Ms. Bronwen Bastone Chief People Officer Mr. Matthew R. Campobasso General Counsel & Corporate Secretary Mr. Oleg Movchan Chief Executive Officer & Director Mr. Neal Pawar Chief Operating Officer Mr. Daniel Groman Chief Technology Officer Mr. Joseph Defeo Global Head of Managed Services Production Mr. Jeff Young Head of Implementation Mr. Bradley Herring Chief Financial Officer Mr. Stephen Malherbe Managing Partner